Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in all patients

From: A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study

Characteristics

Univariate

 

Multivariate

  
 

HR

95% CI

p

HR

95% CI

p

Age (years)

 ≤18

1

 

0.006

1

 

0.587

 >18

1.654

1.160-2.361

 

1.105

0.770-1.587

 

Sex

 Male

1

 

0.281

   

 Female

0.809

0.551-1.189

    

location

 Extremities

1

 

0.264

   

 Non-extremities

1.340

0.802-2.240

    

Tumor size

 ≤8cm

1

 

<0.001

1

 

0.015

  >8cm

2.502

1.730-3.628

 

1.647

1.101-2.464

 

Enneking

 I

1

 

<0.001

1

 

<0.001

 II

5.164

2.073-12.864

 

3.206

1.249-8.229

 

 III

11.484

4.539-29.057

 

6.650

2.569-17.216

 

Subtype

 Conventional osteosarcoma

1

 

0.612

   

 Telangiectatic osteosarcoma

1.619

0.781-3.356

0.196

   

 Small cell osteosarcoma

0.352

0.049-2.531

0.300

   

 Parosteal osteosarcoma

1.008

0.573-1.775

0.977

   

 Periosteal osteosarcoma

0.344

0.048-2.473

0.289

   

 High grade surface osteosarcoma

1.335

0.185-9.620

0.775

   

 Low-grade central osteosarcoma

0.851

0.475-1.526

0.589

   

Pathological fracture

 No

1

 

0.905

   

 Yes

0.967

0.554-1.688

    

Surgery

 No

1

 

0.302

   

 Yes

0.768

0.466-1.267

    

NACT

 No

1

 

0.001

1

 

0.017

 Yes

0.557

0.391-0.793

 

0.641

0.446-0.923

 

alkaline phosphatase

 Normal

1

 

0.016

1

 

0.319

 Elevated

1.574

1.089-0.273

 

1.216

0.828-1.786

 

CAR

 LCAR

1

  

1

 

<0.001

 HCAR

3.284

2.278-4.736

<0.001

2.265

1.535-3.343

 

PLR

 LPLR

1

 

0.001

1

 

0.977

 HPLR

1.825

1.272-2.619

 

1.006

0.675-1.498

 

NLR

 LNLR

1

 

<0.001

1

 

0.001

 HNLR

2.794

1.874-4.165

 

2.001

1.309-3.058

 
  1. CAR C-reactive protein-to-albumin ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, NACT neoadjuvant chemotherapy